Stockscreener 앱 받기
0.00
100.00%
-2.11
전일 마감가:
$2.11
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$45.72M
수익:
-
순이익/손실:
$-12.94M
주가수익비율:
0.00
EPS:
-2.84
순현금흐름:
$-13.83M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$7.42
애일러론 테라 Stock (ALRN) Company Profile
명칭
Aileron Therapeutics Inc
전화
(737) 802-1989
주소
12407 N. MOPAC EXPY., AUSTIN, MA
ALRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALRN
Aileron Therapeutics Inc
|
0.00 | 45.72M | 0 | -12.94M | -13.83M | -2.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.83 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.06 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
606.39 | 36.98B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.01 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
242.75 | 26.15B | 3.81B | -644.79M | -669.77M | -6.24 |
애일러론 테라 Stock (ALRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2017-07-24 | 개시 | BofA/Merrill | Buy |
| 2017-07-24 | 개시 | Jefferies | Buy |
| 2017-07-24 | 개시 | William Blair | Outperform |
애일러론 테라 주식(ALRN)의 최신 뉴스
Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F - PR Newswire
Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PR Newswire
Rein's IPF Drug Shows Promise: 4 Biomarkers Hit Statistical Significance in Phase 1b - Stock Titan
Aileron Therapeutics, Inc. Announces New Appointments - MarketScreener
Peripheral T-cell Lymphoma Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Companies & Growth Analysis Report by DelveInsight - The Globe and Mail
Reflecting On Productivity Software Stocks’ Q4 Earnings: Dropbox (NASDAQ:DBX) - The Globe and Mail
Artivion (AORT): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
Better Artificial Intelligence Stock: SoundHound AI vs. C3.ai - The Globe and Mail
Did Robinhood Just Say Checkmate to SoFi? - The Globe and Mail
Firing on All Cylinders: Benchmark (NYSE:BHE) Q4 Earnings Lead the Way - The Globe and Mail
Stocks in play: i-80 GOLD CORP. - The Globe and Mail
Lucid (LCID): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
Are XPeng (XPEV) Traders Overpricing Options Ahead of Q4 Earnings? - The Globe and Mail
Will Gasoline Prices Head Higher During the 2025 Driving Season? - The Globe and Mail
Snowflake (SNOW) Q4 Earnings Report Preview: What To Look For - The Globe and Mail
Chemotherapy Induced Anemia Drugs Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, NDA Approvals, Therapies, and Companies by DelveInsight - The Globe and Mail
Chemotherapy Induced Anemia Drugs Market 2032: EMA, PDMA, FDA - openPR
Hypoxia Treatment Market to Witness Substantial Growth by 2031 | - openPR
Theratechnologies (NASDAQ:THTX) vs. Aileron Therapeutics (NASDAQ:ALRN) Head to Head Survey - Defense World
Aileron Therapeutics Reports Q3 2024 Financial Results - MSN
Lockheed Martin Earnings: What To Look For From LMT - The Globe and Mail
Aileron Therapeutics, Inc. announced that it has received $42 million in funding from a group of investors. - Marketscreener.com
Aileron straps in for 2025 with a new name: Rein Therapeutics - Fierce Pharma
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma - Marketscreener.com
Aileron Therapeutics, Inc. Announces Board Changes - Marketscreener.com
Aileron Therapeutics, Inc. Announces Board Changes -April 01, 2019 at 06:16 am EDT - Marketscreener.com
Aileron Therapeutics to be Included in the Russell Microcap® Index - Marketscreener.com
Aileron Therapeutics Announces Appointments to Scientific Advisory Board -March 28, 2018 at 07:00 am EDT - Marketscreener.com
Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer - Marketscreener.com
Aileron Therapeutics Announces Board Appointments - Marketscreener.com
Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - Marketscreener.com
Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights - Marketscreener.com
Aileron Therapeutics, Inc. Announces Management Changes - Marketscreener.com
Aileron Therapeutics Announces Management Changes - Marketscreener.com
Aileron Therapeutics, Inc. Announces CEO Changes - Marketscreener.com
Aileron Therapeutics Announces Management Changes -September 06, 2018 at 09:10 am EDT - Marketscreener.com
Rein Therapeutics announces name change and new ticker By Investing.com - Investing.com Canada
Rein Therapeutics announces name change and new ticker - Investing.com
Aileron Therapeutics announces rebranding to Rein Therapeutics - MSN
Geode Capital Management LLC Grows Position in Aileron Therapeutics, Inc. (NASDAQ:ALRN) - Defense World
Geode Capital Management LLC Boosts Stock Position in Pro-Dex, Inc. (NASDAQ:PDEX) - Defense World
Aileron Therapeutics Announces Rebranding to Rein Therapeutics - PR Newswire
Aileron Therapeutics to Present at the 8th Annual IPF Summit - The Eastern Progress Online
Aileron Therapeutics CEO James Brian Windsor buys $897 in stock By Investing.com - Investing.com Nigeria
Aileron Therapeutics CEO James Brian Windsor buys $897 in stock - Investing.com
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - The Eastern Progress Online
Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Decrease in Short Interest - MarketBeat
Chemotherapy Induced Anemia Treatment Market 2032: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight - Barchart
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Citizentribune
Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 8.7% in October - MarketBeat
Aileron Therapeutics Inc (ALRN) Quarterly 10-Q Report - Quartzy
애일러론 테라 (ALRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.71%
자본화:
|
볼륨(24시간):